Research today. Impact tomorrow.

25% Off the entire catalogue →

Same standards. Greater possibilities.

Research Use Only18+Not for Human ConsumptionReconstitution Materials Not Supplied
Peptide Database

Metabolic & GLP-1 research

HGH Fragment 176-191 (HGH Frag): Research Overview

The tail end of the growth hormone molecule, studied for effects on fat metabolism.

Also known as HGH Frag · growth hormone fragment 176-191

Research use onlyStrongest evidence: animal studyReviewed
DatabaseReferences

What is HGH Fragment 176-191?

HGH Fragment 176-191 is the fat-burning segment of human growth hormone, corresponding to amino acids 176 through 191 of the full GH molecule. It stimulates lipolysis and inhibits lipogenesis without the growth-promoting or insulin-disrupting effects associated with full-length HGH. AOD-9604 is a modified version of this fragment with an added N-terminal tyrosine residue.

What is HGH Fragment 176-191 researched for?

  • Increases fat oxidation and breakdown of stored triglycerides in adipose tissue without affecting glucose homeostasis.
  • Reduces new fat synthesis and storage, complementing the lipolytic action for overall fat reduction.
  • Promotes selective fat loss while preserving lean mass, particularly effective when combined with a caloric deficit and exercise.

How does HGH Fragment 176-191 work?

Mimics the lipolytic region of human growth hormone by stimulating fat breakdown through beta-3 adrenergic receptor pathways. Unlike full HGH, it does not bind the growth hormone receptor, so it does not increase IGF-1 levels or interfere with glucose metabolism. The fragment selectively targets adipose tissue to promote fat oxidation.

Reported targets: adrenergic receptor

References

  1. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment

    Heffernan MA, Thorburn AW, Fam B, et al. · International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity · 2001

    Both hGH and the C-terminal fragment (176-191) reduced body weight gain, increased fat oxidation, and stimulated lipolysis in obese ob/ob mice without affecting glucose metabolism.

    Animal study · PMID 11673763

  2. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice

    Heffernan M, Summers RJ, Thorburn A, et al. · Endocrinology · 2001

    The hGH fragment and its modified form AOD-9604 both increased beta-3 adrenergic receptor expression in obese mice. Effects were abolished in beta-3-AR knockout mice, confirming this receptor pathway is essential for the lipolytic action.

    Animal study · PMID 11713213

  3. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone

    Ng FM, Sun J, Sharma L, et al. · Hormone research · 2000

    Characterized the metabolic properties of the hGH 176-191 lipolytic domain, demonstrating antilipogenic activity independent of the growth hormone receptor.

    PMID 11146367

  4. Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism

    Heffernan MA, Jiang WJ, Thorburn AW, et al. · American journal of physiology. Endocrinology and metabolism · 2000

    Oral treatment with the synthetic hGH fragment for 30 days significantly reduced body weight gain and altered lipogenic and lipolytic activity in adipose tissue of obese mice.

    Animal study · PMID 10950816